Confocal NL appoints Christoph van der Reijden as its new CTO a.i. and thanks Stefan Lampaert for his tremendous contributions to growing Confocal NL into a successful company today.
“I had the privilege of leading the incubation and development of the Point and Line REscan Confocal Microscopes. It has been an exciting and rewarding journey, allowing me to collaborate with an exceptionally talented and passionate team.” said Stefan Lampaert.
Pim Vos, CEO of Confocal NL, added, “We would like to thank Stefan for his amazing contribution to this company. His commitment and sheer focus have allowed the faster development of our products, enabling scientists around the world to accelerate their research. We wish Stefan all the best for his future career steps. Meanwhile, we are excited to welcome Christoph van der Reijden to Confocal NL! We are certain that his extensive experience in the imaging & medical industry will accelerate the development of our confocal systems even further.”
“I’m excited to join Confocal NL for its people, disruptive technology, and products that enable truly gentle live cell imaging. I look forward to working with the teams to unlock the full potential and impact of the confocal systems for researchers around the globe”, said Christoph van der Reijden.
Mr. van der Reijden is a seasoned technical professional with extensive experience in research & development of medical imaging, diagnostics, acoustics, and spanning research. He is highly skilled in optical imaging, microscopy, ESD safety, and signal processing, with a proven ability to enhance product functionality and usability.
Highlights from his experience include developing innovative solutions such as a surgical imaging system to differentiate diseased tissue using fluorescence at Quest Medical Imaging, and a reagent production instrument for blood analyzers now widely sold at RR Mechatronics. His expertise also includes designing and verifying hardware and software, applying statistical methods for design validation, and leading quality compliance efforts, including FDA applications.